Bio-Rad Laboratories (BIO)

NYSE Health Care Life Sciences Tools & Services S&P MidCap 400
$381.57
+12.57 (+3.41%)
Close of Nov 06, 2026 · end-of-day data
Source: Bio-Rad Laboratories's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 09, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$2.07B$2.16B$2.29B$2.31B$2.55B$2.92B$2.80B$2.67B$2.57B$2.58B
Cost of revenue$929.74M$972.45M$1.07B$1.05B$1.11B$1.28B$1.23B$1.24B$1.19B$1.24B
Gross profit$1.14B$1.19B$1.22B$1.26B$1.44B$1.64B$1.57B$1.43B$1.38B$1.34B
Research & development$205.71M$250.16M$199.20M$202.71M$217.76M$260.64M$256.90M$247.40M$295.90M$275.60M
Selling, general & admin$814.70M$806.79M$834.78M$824.62M$798.80M$877.12M$827.80M$841.70M$814.00M$844.30M
Operating income$55.72M$119.25M-$103.34M$229.66M$421.33M$500.34M$482.60M$337.80M$269.00M$47.20M
Interest expense$23.38M$23.01M$23.96M$23.42M$21.86M$1.55M$38.10M$49.40M$48.90M$49.00M
Pre-tax income$41.56M$97.81M$512.66M$2.26B$4.92B$5.45B-$4.70B-$850.10M-$2.34B$995.50M
Income tax$15.56M-$24.44M$147.04M$502.41M$1.10B$1.19B-$1.08B-$212.80M-$498.30M$235.60M
Net income$26.00M$122.25M$365.61M$1.76B$3.81B$4.25B-$3.63B-$637.30M-$1.84B$759.90M
EBITDA$198.62M$267.95M$34.76M$363.86M$559.93M$637.94M$619.90M$483.70M$420.60M$212.60M
EPS (basic)$0.88$4.12$12.25$58.93$128.13$142.61$-121.79$-21.82$-65.36$27.87
EPS (diluted)$0.88$4.07$12.10$58.27$126.47$140.83$-121.79$-21.82$-65.36$27.85
Diluted shares29.65M30.03M30.23M30.18M30.16M30.21M29.79M29.21M28.21M27.28M
Gross margin55.0%55.0%53.4%54.4%56.5%56.1%55.9%53.4%53.7%51.9%
Operating margin2.7%5.5%-4.5%9.9%16.6%17.1%17.2%12.6%10.5%1.8%
Net margin1.3%5.7%16.0%76.1%149.8%145.6%-129.5%-23.9%-71.9%29.4%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$456.26M$383.82M$431.53M$660.67M$662.21M$470.78M$434.20M$403.80M$488.10M$529.80M
Short-term investments$383.18M$371.15M$413.27M$453.97M$328.91M$399.13M$1.36B$1.20B$1.18B$1.01B
Receivables$372.35M$464.85M$392.44M$392.67M$419.42M$423.54M$494.64M$489.00M$452.50M$460.60M
Inventory$524.96M$594.80M$583.82M$554.01M$622.25M$572.24M$719.32M$780.50M$760.00M$740.70M
Total current assets$1.84B$1.98B$2.02B$2.18B$2.14B$1.99B$3.16B$3.05B$3.03B$2.91B
Goodwill$477.10M$506.10M$219.80M$264.10M$291.90M$347.30M$406.50M$413.60M$410.50M$579.80M
Total assets$3.85B$4.27B$5.61B$8.01B$12.97B$17.80B$13.50B$12.30B$9.36B$10.58B
Total current liabilities$471.32M$502.70M$450.80M$905.50M$631.54M$680.94M$568.71M$522.80M$467.80M$517.00M
Long-term debt$434.19M$434.58M$438.94M$13.58M$12.26M$10.51M$1.20B$1.20B$1.20B$1.20B
Total debt$434.19M$434.58M$438.94M$13.58M$12.26M$10.51M$1.20B$1.20B$1.20B$1.20B
Total liabilities$1.27B$1.34B$1.59B$2.25B$3.09B$4.11B$3.89B$3.56B$2.79B$3.12B
Shareholders' equity$2.58B$2.93B$4.02B$5.76B$9.89B$13.69B$9.62B$8.74B$6.57B$7.45B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$216.07M$104.14M$285.49M$457.90M$584.97M$669.46M$194.40M$374.90M$455.20M$532.20M
Capital expenditures$141.44M$111.33M$129.82M$98.53M$108.56M$133.75M$112.80M$156.70M$165.60M$157.60M
Free cash flow$74.63M-$7.20M$155.67M$359.37M$476.41M$535.72M$81.60M$218.20M$289.60M$374.60M
Investing cash flow-$213.88M-$175.57M-$186.98M-$208.89M-$69.89M-$797.38M-$1.21B$20.20M-$160.20M-$189.70M
Financing cash flow$9.02M$341.00K-$48.68M-$22.76M-$523.04M-$55.43M$973.60M-$425.60M-$218.80M-$283.20M
Share buybacks$0$2.92M$48.91M$28.00M$100.00M$50.00M$215.70M$428.70M$203.60M$295.50M
Stock-based compensation$19.70M$23.40M$27.80M$35.60M$41.60M$51.20M$60.90M$61.30M$62.30M$58.00M
Depreciation & amortization$142.90M$148.70M$138.10M$134.20M$138.60M$137.60M$137.30M$145.90M$151.60M$165.40M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.